This decrease was partially offset by the receipt of $8.7 million from sales of common stock under the Cantor agreement. At June 30, 2017, Celldex had 127.4 million shares outstanding. Revenues: Total revenue was $3.8 million in the …
A year ago, they were trading at $3.09. This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on CLDX at https://www.zacks.com/ap/CLDX
Needham & Co downgrades Celldex Therapeutics Inc. (Nasdaq ... as timelines are likely to be delayed and there is limited near-term newsflow to drive the stock valuation." Celldex Therapeutics, Inc., formerly AVANT …
--(BUSINESS WIRE)--AVANT Immunotherapeutics ... 2008 and shares of the Company’s common stock will be listed on NASDAQ under the ticker symbol “CLDX” effective at market opening on the same day. The Board of Directors also …
Analysts adjusted their ratings and price targets on Celldex Therapeutics, Inc. (CLDX), EP Energy Corp ... Today's loss represents quite the setback for a stock that had been steadily gaining ground since hitting a two-year low of $160.84 in …
The stock imploded last year after brain cancer patients in the first control group tested against its former lead candidate outperformed historical survival data by a wide margin. When Rintega failed spectacularly, Celldex was lucky enough …
so the stock should be in strong hands. Once it gets moving higher, you shouldn’t see a lot of sellers. This is the strategy that helped my subscribers earn a gain of 775% on NPS Pharmaceuticals, Inc.(NASDAQ:NPSP) and more than 400% …
stock options, or bonds from: Altor BioScience Corp.; Celldex Therapeutics, Inc.; CytoMX Therapeutics Other: Named on a patent by Moffitt Cancer Center; …
This decrease was partially offset by the receipt of $11.2 million from sales of common stock under the Cantor agreement. At September 30, 2017, Celldex had 132.1 million shares outstanding. Revenues: Total revenue was $3.9 million in the …